What's new on antithrombotics?;Que retenir de la littérature récente concernant les antithrombotiques ?

Annales de Cardiologie et d'Angeiologie

Volumn 58, Issue 4, 2009, Pages 230-235

  Helft, G ^a   Leger, P ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Service de cardiologie   (France)

Author keywords

Anticoagulant; Antithrombotic; Coronary artery disease; Recommendations; Thrombosis; Venous thromboembolism disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; COUMARIN DERIVATIVE; DABIGATRAN ETEXILATE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; IDRAPARINUX; OTAMIXABAN; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MONITORING; HEART MUSCLE ISCHEMIA; HIP ARTHROPLASTY; HUMAN; LUNG EMBOLISM; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROPHYLAXIS; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; STENT THROMBOSIS; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

FIBRINOLYTIC AGENTS; HUMANS; THROMBOEMBOLISM;

EID: 68349152987     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2008.07.016     Document Type: Short Survey

References (9)

1. The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357 (2007) 1094-1104
2. The van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357 (2007) 1104-1112
3. Eriksson B.I., Dahl O.E., Rosencher N., et al. Dabogatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370 (2007) 949-956
4. Glynn R.J., Ridker P.M., Goldhaber S.Z., and Buring J.E. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 147 (2007) 525-533
5. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 (2007) 217-227
6. Cohen M., Bhatt D.L., Alexander J.H., et al. Randomized, double-blind, dose ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in pzercutaneous coronary intervention. The SEPIA-PCI trial. Circulation 115 (2007) 2642-2651
7. Wiviot S.D., Braunwald E., Mccabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med (2007)
8. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28 (2007) 1598-1660
9. Spaulding C., Daemen J., Boersma E., Cutlip D., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997